BWM
JNCE

Baystate Wealth Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Baystate Wealth Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5
Closed – – 790
2020
Q3 		$0 Buy
+5
New +$31 ﹤0.01% 766

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Baystate Wealth Management's JNCE Position: Q4 2020 in Review

Baystate Wealth Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2020, closing a stake of 5 shares.

Baystate Wealth Management first reported a position in JNCE in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 104 funds tracked by Wall St. Rank hold JNCE as of Q4 2020.

  • Baystate Wealth Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Baystate Wealth Management sold 5 Jounce Therapeutics, Inc. Common Stock shares in Q4 2020.
  • Baystate Wealth Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Baystate Wealth Management's Jounce Therapeutics, Inc. Common Stock position peaked at $0 in Q3 2020.
  • 104 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Baystate Wealth Management's 13F filing for Q4 2020, filed 15 Jan 2021.